Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
BNF presentation directory
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
- Chemical substance: Mycophenolate mofetil
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Mycophenolate mofetil 500mg tablets
0802010M0AAABAB
|
Mycophenolate mofetil (Systemic) | Mycophenolate mofetil | Malignant Disease and Immunosuppression | 37,330 |
|
Mycophenolate mofetil 250mg capsules
0802010M0AAAAAA
|
Mycophenolate mofetil (Systemic) | Mycophenolate mofetil | Malignant Disease and Immunosuppression | 9,894 |
|
CellCept 500mg tablets
0802010M0BBABAB
|
CellCept | Mycophenolate mofetil | Malignant Disease and Immunosuppression | 2,413 |
|
Mycophenolate mofetil 1g/5ml oral suspension sugar free
0802010M0AAAJAJ
|
Mycophenolate mofetil (Systemic) | Mycophenolate mofetil | Malignant Disease and Immunosuppression | 978 |
|
CellCept 250mg capsules
0802010M0BBAAAA
|
CellCept | Mycophenolate mofetil | Malignant Disease and Immunosuppression | 965 |
|
Myfenax 500mg tablets
0802010M0BCAAAB
|
Myfenax | Mycophenolate mofetil | Malignant Disease and Immunosuppression | 590 |
|
Myfenax 250mg capsules
0802010M0BCABAA
|
Myfenax | Mycophenolate mofetil | Malignant Disease and Immunosuppression | 204 |
|
CellCept 1g/5ml oral suspension
0802010M0BBAEAJ
|
CellCept | Mycophenolate mofetil | Malignant Disease and Immunosuppression | 110 |
|
Arzip 250mg capsules
0802010M0BDAAAA
|
Arzip | Mycophenolate mofetil | Malignant Disease and Immunosuppression | No data available |
|
Arzip 500mg tablets
0802010M0BDABAB
|
Arzip | Mycophenolate mofetil | Malignant Disease and Immunosuppression | No data available |
|
CellCept 500mg powder for solution for infusion vials
0802010M0BBADAH
|
CellCept | Mycophenolate mofetil | Malignant Disease and Immunosuppression | No data available |
|
Mycophenolate mofetil 100mg/5ml oral suspension
0802010M0AAAGAG
|
Mycophenolate mofetil (Systemic) | Mycophenolate mofetil | Malignant Disease and Immunosuppression | No data available |
|
Mycophenolate mofetil 125mg/5ml oral suspension
0802010M0AAAIAI
|
Mycophenolate mofetil (Systemic) | Mycophenolate mofetil | Malignant Disease and Immunosuppression | No data available |
|
Mycophenolate mofetil 250mg/5ml oral suspension
0802010M0AAACAC
|
Mycophenolate mofetil (Systemic) | Mycophenolate mofetil | Malignant Disease and Immunosuppression | No data available |
|
Mycophenolate mofetil 300mg/5ml oral suspension
0802010M0AAADAD
|
Mycophenolate mofetil (Systemic) | Mycophenolate mofetil | Malignant Disease and Immunosuppression | No data available |
|
Mycophenolate mofetil 500mg inf vials
0802010M0AAAHAH
|
Mycophenolate mofetil (Systemic) | Mycophenolate mofetil | Malignant Disease and Immunosuppression | No data available |
|
Mycophenolate mofetil 500mg/5ml oral suspension
0802010M0AAAEAE
|
Mycophenolate mofetil (Systemic) | Mycophenolate mofetil | Malignant Disease and Immunosuppression | No data available |
Why monitor BNF codes?
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Understand demand drivers
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.